Výsledky vyhledávání - "Michela Manzotti"

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer

Autor: Chiara Catania, Godefridus J. Peters, Elisa Giovannetti, Lorenzo Spaggiari, Giuseppe Pelosi, Lars Petter Jordheim, Davide Radice, Michela Manzotti, Mariacarmela Santarpia, Francesca Toffalorio, Filippo de Braud, Gianluca Spitaleri, Niccola Funel, Carmelo Tibaldi, Tommaso De Pas, Christopher Adrian Jaramillo

Publikováno v: Oncotarget
Oncotarget, 9(23), 16437-16450. Impact Journals
Oncotarget 9 (2018): 16437–16450. doi:10.18632/oncotarget.24505
info:cnr-pdr/source/autori:Toffalorio F.; Santarpia M.; Radice D.; Jaramillo C.A.; Spitaleri G.; Manzotti M.; Catania C.; Jordheim L.P.; Pelosi G.; Peters G.J.; Tibaldi C.; Funel N.; Spaggiari L.; de Braud F.; De Pas T.; Giovannetti E./titolo:5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine%2Fplatinum combination chemotherapy in non-small cell lung cancer/doi:10.18632%2Foncotarget.24505/rivista:Oncotarget/anno:2018/pagina_da:16437/pagina_a:16450/intervallo_pagine:16437–16450/volume:9
Toffalorio, F, Santarpia, M, Radice, D, Jaramillo, C A, Spitaleri, G, Manzotti, M, Catania, C, Jordheim, L P, Pelosi, G, Peters, G J, Tibaldi, C, Funel, N, Spaggiari, L, de Braud, F, de Pas, T & Giovannetti, E 2018, ' 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer ', Oncotarget, vol. 9, no. 23, pp. 16437-16450 . https://doi.org/10.18632/oncotarget.24505

// Francesca Toffalorio 1, 2, * , Mariacarmela Santarpia 1, 3, * , Davide Radice 4 , Christopher Adrian Jaramillo 5 , Gianluca Spitaleri 1, 6 , Michela Manzotti 7 , Chiara Catania 1, 6 , Lars Petter Jordheim 8 , Giuseppe Pelosi 9, 10 , Godefridus J.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad5ff4d7a93c71d7aa1fa8fe88939d8
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044440588&origin=inward

Zobrazit plný text záznamu

Prognostic value of human papillomavirus in anal squamous cell carcinoma

Autor: Massimo Barberis, Elena Magni, Paola Simona Ravenda, Maria Cristina Leonardi, Mario Sideri, Edoardo Botteri, Veronica Dell’Acqua, Nicola Fazio, Michela Manzotti, Davide Vacirca, Maria Giulia Zampino, Cristina Trovato

Publikováno v: Cancer Chemotherapy and Pharmacology. 74:1033-1038

Anal cancer is an uncommon malignancy, but its incidence is increasing worldwide. Chemoradiation is the standard primary treatment for patients with loco-regional limited disease. However, once patients develop metastatic spread, the prognosis is ver

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ec02cc336ebe1731d06dacdd292664
https://doi.org/10.1007/s00280-014-2582-x

Zobrazit plný text záznamu

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

Autor: Lorenzo Preda, Cristina Noberasco, Chiara Lazzari, Tommaso De Pas, Francesca Toffalorio, Fabio Conforti, Massimo Barberis, Gianluca Spitaleri, Filippo de Marinis, Chiara Catania, Michela Manzotti

Publikováno v: OncoTargets and therapy

We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edc53b91a9680ed5b2f39d9b3814c5f5
http://europepmc.org/articles/PMC4020909

Zobrazit plný text záznamu

Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients

Autor: Giancarlo Pruneri, Paolo Radice, Massimo Barberis, Marco Colleoni, Monica Barile, Giuseppe Viale, Caterina Fumagalli, P. Possanzini, Irene Feroce, Patrick Maisonneuve, Michela Manzotti, Bernardo Bonanni

Publikováno v: Breast Cancer Research and Treatment. 134:131-137

Triple-negative breast cancers are characterized by the triple-negative (ER/PgR/Her2 negative) phenotype, are frequently associated with BRCA gene mutation, and are not candidate to currently available endocrine and HER2-targeted treatments. MGMT is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b0849e035c0c111df1f35442e4c3540
https://doi.org/10.1007/s10549-011-1945-9

Zobrazit plný text záznamu

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

Autor: Filippo de Braud, Gianluca Spitaleri, Massimo Barberis, Lorenzo Spaggiari, Tommaso De Pas, M. Giovannini, Chiara Catania, Caterina Fumagalli, Angelo Delmonte, Francesca Toffalorio, Michela Manzotti

Publikováno v: Journal of Thoracic Oncology. 6(11):1895-1901

Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib. Although the "common" EGFR mutations, such as the L858R point mutat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4372e1ef7749ef8d1fa37881c2693f7a

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání